猫的阿米奥达龙治疗:说明,不良反应和生存结果的评估
Graham C Rossi1, Sonja S Tjostheim1, Heidi B Kellihan1
1Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, United States.
Frontiers in veterinary science
|February 3, 2025
概括
艾米奥达龙用于猫室内心跳,在37%的猫中出现过渡性胃肠道症状. 没有观察到任何显著的实验室变化,但同时发生的心律失常会增加死亡风险.
科学领域:
- 兽医心脏病学 兽医心脏病学
- 伴侣动物的药理学
背景情况:
- 阿米奥达龙是一种用于兽医的抗心律失常药物.
- 关于猫慢性使用阿米奥达龙的不良影响和结果的数据有限.
研究的目的:
- 描述与猫的慢性阿米奥达龙治疗相关的临床不良反应和生化变化.
- 为了评估用阿米奥达龙治疗的猫的生存结果.
主要方法:
- 追溯的,多中心的队列研究.
- 在2016年至2022年期间,审查了27只用阿米奥达龙治疗的猫的医疗记录.
- 收集了关于信号,心脏病,并发症,阿米奥达龙剂量,实验室结果,不良事件和存活率的数据.
主要成果:
- 艾米奥达龙主要用于心室低心率 (70%),中位数剂量为8.8 mg/kg/天.
- 37%的猫发生过渡性缺氧或吐;没有发现任何显著的实验室异常.
- 平均存活时间为441天;同时发生的心室和心室上心动节律失常症显著增加了死亡风险 (HR 12.9).
结论:
- 艾米奥达龙可用于猫科室心律失常症,具有过渡性胃肠道副作用.
- 在慢性阿米奥达龙治疗期间,没有发现任何显著的实验室异常.
- 同时发生的上心室和心室动脉节律失常症与用阿米奥达龙治疗的猫的预后较差有关.
相关概念视频
Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
892
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
892
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
705
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
705
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311


